Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. - Wikidata - awgldk - TriplyDB

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.

http://www.wikidata.org/entity/Q42997897

about

Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization Metabolic factors and chronic hepatitis C: a complex interplay Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3 Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?Predicting the outcomes of combination therapy in patients with chronic hepatitis C using artificial neural network.Distinct patterns of the lipid alterations between genotype 1 and 2 chronic hepatitis C patients after viral clearance Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.Effects of statins on the risk of hepatocellular carcinoma Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism.Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.The impact of host factors on management of hepatitis C virus.Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments.Hepatitis C virus infection and nonalcoholic steatohepatitis Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study.Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.Status of essential trace minerals and oxidative stress in viral hepatitis C patients with nonalcoholic fatty liver disease Demographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north India Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease.Chemoprevention for hepatocellular carcinoma: the role of statins.Individualization of chronic hepatitis C treatment according to the host characteristics.Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.Unique ties between hepatitis C virus replication and intracellular lipids.Multifaceted roles for lipids in viral infection.Metabolic alterations and chronic hepatitis C: treatment strategies.New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials.Clinical perspective: statins and the liver--harmful or helpful?Lipids and HCV.Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3.Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy?Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality Statins and liver injury.Statin therapy in patients with cirrhosis.Genotype 3 and higher low-density lipoprotein levels are predictors of good response to treatment of recurrent hepatitis C following living donor liver transplantation.Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients.Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta-analysis.

P2860

Q26779128-615CF029-1185-42A0-A8C6-CD1DAECF582A Q26864485-D8B658F1-EE60-4A5E-8849-C253DF62871B Q27011787-914F8187-D5DF-4BD5-B875-71B779E95D17 Q28081216-B59C5E2C-3042-42DE-903C-5226D3BC4E46 Q28534715-2C27158F-ADC4-4B92-9211-7C8E35FEDD05 Q28543090-6A32ADF7-8B83-4C9C-AF94-E9F9F3D1033A Q30369757-DD9E7CBC-DDE4-4E5D-86E9-5E2A20535DB6 Q33808119-B318D53C-40A9-4547-BC77-2AF10197EEA8 Q34046758-A9A15752-263D-476E-B74B-362FCDCDC13F Q34177249-BD774BCC-E245-4EBC-8F19-A9B31CE24A30 Q34997752-57F67ED5-CFEF-4374-91CF-79355C60E2C1 Q35027939-9CE8AC42-44E8-4A76-8205-32E47EB1F83A Q35048926-4D1B014F-3CDE-4498-B95B-CA83D292BC67 Q35122536-443E0456-08A1-46BF-9931-0276BD152D3F Q35990066-0CC1DE8D-CC67-49D1-9487-F8C4C9BD73CB Q36026554-0BAF52CA-3DCF-4DB0-B17E-19F126941ACC Q36179898-C5B37601-1A89-4BD7-AEF3-5AB7B1DD7A46 Q36379566-662FE8C2-1C66-4143-AE1A-5ACAE0BEA2F5 Q36457831-826A15F8-506A-436A-8551-F848EBBFE93C Q36800914-63C000AA-00CE-45DD-AB99-60DB47AFE98A Q36966151-C859FAEF-87A8-4558-A2A5-E27E668429DA Q37015738-0DC35D31-6D79-44FE-BB3B-DF68F876FA50 Q37584611-9AF84B3C-E84D-4A98-B569-C0A2A75B3688 Q37654502-AAE0C788-038C-411C-9FCA-9AE52D0AE4A2 Q37699395-500AA876-1AE4-4E58-B9A6-B68B5E343D2C Q37865821-A90D97D0-A889-414E-8985-4612494C071A Q37870334-F71DF532-335F-4C45-AA14-C462C4DB440F Q37924816-9D7C1787-8A30-48B5-8110-1AC5631F2BD5 Q37993889-5F1DD5E4-4225-4894-8322-DDD84956B0BE Q38009719-9014597B-34B2-497F-9D5A-833F0870C1B9 Q38056643-8AE6216D-6AF3-4815-BD59-9AD1106930B8 Q38134774-57489301-E3EF-420C-B2C9-99DF1B8000DF Q38170504-9E57D62D-B0F2-411C-881D-1101889AA965 Q38198618-97A7D2BB-66B6-43E4-94A8-6754399567CB Q38204369-51ECCAFB-0091-48D0-B34A-6BBCC1BCF95D Q38608978-93B08ADF-DDFD-4B57-99BA-65BE73B91BA0 Q38961331-B9AFB7FC-36CF-46B9-94F6-60517946238E Q40707628-66DBE580-66CE-4D25-B203-4058447888FD Q41435455-00A244AC-8448-46F6-9BC4-5EB621B61AA4 Q42211503-A2BBE0E0-A380-488D-BFD2-86BE7D64EB4C

P2860

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.

http://www.wikidata.org/entity/Q42997897

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Serum cholesterol and statin u ...... erferon and ribavirin therapy.

@en

Serum cholesterol and statin u ...... erferon and ribavirin therapy.

@nl

type

label

Serum cholesterol and statin u ...... erferon and ribavirin therapy.

@en

Serum cholesterol and statin u ...... erferon and ribavirin therapy.

@nl

prefLabel

Serum cholesterol and statin u ...... erferon and ribavirin therapy.

@en

Serum cholesterol and statin u ...... erferon and ribavirin therapy.

@nl

P1433

Q42997897-45E83C22-79C2-4069-B20E-9F8B6015D796

P1476

Q42997897-A9618E2F-3268-4FFE-9B7D-0C322918E89F

P2093

Q42997897-04449A70-C503-4388-B26B-DEFC51A695B3

Q42997897-051167BC-0B70-47E0-A540-2FDAD7075DA6

Q42997897-2FF16C8D-F0BF-45D0-9968-EF0DA431CB34

Q42997897-4774BE1F-78A2-4E1E-8ED2-109013A38758

Q42997897-555DA109-3F0F-4D81-8923-ADFCE453EF4C

Q42997897-7F93A890-DB7E-45EE-9801-4B74964D9420

Q42997897-9109643C-9430-4936-8DFC-045A1BF1A229

Q42997897-A3A54DD0-BAD7-4009-8021-C6AB66471428

Q42997897-A9AE1A25-7B09-4FD3-8C03-A3A00C62F630

Q42997897-BAC4E543-631E-430F-AEDE-5ABA5824AD3F

P2860

Q42997897-0B7683FB-FA6B-4AC7-8DD2-CF7A09E4E009

Q42997897-0D29C24F-2953-4143-AB62-3C555325D7BB

Q42997897-0ED33CB7-1862-4346-976B-A955AFA1E289

Q42997897-1B99419D-F385-4275-A4F9-E8A37194D3A2

Q42997897-2B0CA03D-5803-4A94-A395-2EEF606DFC44

Q42997897-33D5656A-6D9A-4E06-864B-C6A084745F0A

Q42997897-34533985-26A4-476C-86C8-F89699A9B491

Q42997897-3486CFCF-6D35-4040-A87E-250A7C095033

Q42997897-364557D2-F4C8-46CB-98CC-3D2F69394571

Q42997897-370B1B38-6C28-452B-A135-1A836923D841

P304

Q42997897-C810C0E2-1B46-4511-A4BC-8DBCE87BFA4E

P31

Q42997897-6DEA72F5-D306-4982-B3A4-BA23DA2DEC77

P356

Q42997897-66196739-0869-4E64-B817-F2868274A2EA

P407

Q42997897-FA501FD4-04A9-4B74-B700-5EA3FF83FC7F

P433

Q42997897-62220ABF-E239-421C-B9B0-F41D09BE5ED1

P478

Q42997897-AC8A9E49-DF5C-438D-B92D-0ED4E0F8D586

P577

Q42997897-76930398-0F93-4F63-AAAE-63DD6405733D

P5875

Q42997897-A2593FB7-B6B2-4E5A-B6D3-7236CC975005

P698

Q42997897-E2C32086-74BB-4A3A-9553-BEBE21B80FBA

P921

Q42997897-90BFBC8B-37F1-496E-9C98-A7C330526D6D

P356

P1433

P1476

Serum cholesterol and statin u ...... erferon and ribavirin therapy.

@en

P2093

Clifford A Brass

http://www.w3.org/2001/XMLSchema#string

Dawn M Torres

http://www.w3.org/2001/XMLSchema#string

Hans Tillmann

http://www.w3.org/2001/XMLSchema#string

Janice K Albrecht

http://www.w3.org/2001/XMLSchema#string

John G McHutchison

http://www.w3.org/2001/XMLSchema#string

Ke-Qin Hu

http://www.w3.org/2001/XMLSchema#string

Kenneth Koury

http://www.w3.org/2001/XMLSchema#string

Keyur Patel

http://www.w3.org/2001/XMLSchema#string

Lorenzo Rossaro

http://www.w3.org/2001/XMLSchema#string

Mark S Sulkowski

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

The global burden of hepatitis C

Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids

Different anti-HCV profiles of statins and their potential for combination therapy with interferon.

Targeting lipid metabolism in the treatment of hepatitis C virus infection.

Fluvastatin inhibits hepatitis C replication in humans.

Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation.

Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment.

Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus.

Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms.

P304

864-874

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.23787

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44692744

http://www.w3.org/2001/XMLSchema#string

P698

20568303

http://www.w3.org/2001/XMLSchema#string

P921